StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
September 1, 2026 3:56 AM
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $112.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst comments "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
